Decoy Therapeutics, Inc.

https://decoytx.com

Decoy Therapeutics, Inc. is a biotechnology company focused on engineering the next generation of peptide conjugate therapeutics to protect and expand patient lives. The company leverages machine learning (ML) and artificial intelligence (AI) tools alongside high-speed synthesis techniques for the rapid design and manufacturing of its drug candidates. Headquartered in Cambridge, Massachusetts, Decoy Therapeutics aims to develop accessible and affordable medicines globally. [1, 2, 3, 4, 8, 11, 13, 15, 16, 17, 19, 21, 22, 24, 25, 26, 28, 29, 32]

The company's core business revolves around its proprietary IMP³ACT platform, which underpins its Designable Multi-Antivirals (D-MAVs). These D-MAVs are engineered to target shared viral mechanisms, moving beyond the traditional one-virus, one-drug model to enable a single, adaptable drug to work across multiple viruses. Decoy Therapeutics' initial pipeline is concentrated on respiratory viruses and gastrointestinal (GI) cancers. Key programs include DCOY-COV, a pan-coronavirus D-MAV targeting high-risk and immunocompromised populations, with a Phase 1 clinical trial anticipated in 2027, and DCOY-TRI, a multi-virus respiratory program designed to address influenza, coronavirus, and paramyxovirus families. [2, 6, 9, 11, 13, 21, 24, 25, 26, 28, 29, 32, 33]

Under the leadership of CEO Rick Pierce, appointed in November 2025, Decoy Therapeutics has undergone significant strategic developments. The company, formerly Salarius Pharmaceuticals, Inc., officially changed its corporate name and began trading under the NASDAQ ticker DCOY on January 8, 2026, following a merger. Recent notable activities include a strategic partnership with Quantori in March 2026 to deploy an AI-driven peptide design and molecular simulation platform, regaining compliance with Nasdaq's minimum bid price requirement in April 2026, and implementing a 1-for-12 reverse stock split in March 2026. Decoy Therapeutics has also secured funding from various sources, including the Massachusetts Life Sciences Seed Fund, Google AI startup program, and NVIDIA Inception program, and received a QuickFire Challenge award from BARDA through BLUE KNIGHT™. [5, 6, 7, 9, 10, 11, 12, 13, 14, 19, 20, 22, 24, 25, 27, 28, 30, 32, 33, 34]

Latest updates

Decoy Therapeutics Showcases AI-Driven Peptide Design at Key Conferences

Event summary

  • Decoy Therapeutics executives will present at the Oligonucleotide & Peptides HubXchange and the Peptide-Based Therapeutics Summit in Boston the week of April 27, 2026.
  • CBO Peter Marschel will lead a roundtable on computational peptide design, highlighting a partnership with Quantori and Google Cloud.
  • CSO Barbara Hibner and CTO Michael Lipp will present preclinical data on D-MAV programs, emphasizing a shift away from traditional one-virus, one-drug approaches.
  • MIT Professor Bradley Pentelute will deliver the opening presentation at the Peptide-Based Therapeutics Summit, focusing on machine learning applications.

The big picture

Decoy's focus on computationally designed, broad-spectrum antivirals represents a significant departure from the traditional 'one-virus, one-drug' paradigm. The company's reliance on AI and partnerships with Google and Quantori positions it at the forefront of a growing trend towards leveraging advanced technologies to address unmet needs in antiviral drug development, but also introduces execution risks associated with complex collaborations and novel therapeutic approaches. The market for broad-spectrum antivirals is substantial, driven by the ongoing threat of emerging infectious diseases and the limitations of current treatments.

What we're watching

Computational Adoption
The success of Decoy's partnership with Quantori and Google Cloud will be critical to accelerating its peptide design process and differentiating it from competitors relying on traditional methods.
Clinical Translation
The presentation of preclinical data at the Peptide-Based Therapeutics Summit will be scrutinized for signs of efficacy and safety, which will influence investor sentiment and future development timelines.
Broad Spectrum Efficacy
The ability of Decoy's D-MAV programs to effectively target a broad range of viruses, particularly the 'tripledemic' of influenza, COVID-19, and RSV, will determine its commercial viability and impact on public health.

Decoy Therapeutics Accelerates Antiviral Pipeline, Eyes Clinical Trials

Event summary

  • Decoy Therapeutics (DCOY) is entering a 'highly catalytic phase' toward clinical development of its antiviral pipeline.
  • The company has partnered with Quantori and Google Cloud to increase computational peptide design capacity by 25-100x.
  • Decoy is advancing DCOY-COV (pan-coronavirus) and DCOY-TRI (multi-virus respiratory) programs, with a Phase 1 trial for DCOY-COV expected in 2027.
  • The company will host a Virtual Investor Closing Bell event on April 9, 2026, at 4:00 PM ET.

The big picture

Decoy Therapeutics is capitalizing on the growing demand for broad-spectrum antiviral solutions and the increasing adoption of AI in drug discovery, positioning itself to address the ongoing threat of viral outbreaks and the need for pandemic preparedness. The company's platform-driven approach, while promising, faces the inherent risks associated with early-stage biotech development and the need to demonstrate clinical efficacy and scalability.

What we're watching

Clinical Execution
The success of the DCOY-COV Phase 1 trial will be critical in validating the D-MAV platform and attracting further investment, and the use of human challenge studies could significantly compress timelines but also introduce regulatory and ethical complexities.
Partnership Dynamics
The effectiveness of the Quantori and Google Cloud partnership in delivering the promised computational capacity increase will determine the speed of candidate discovery and optimization, and the nature of future collaborations will be key to scaling manufacturing and distribution.
Market Validation
The ability of DCOY-TRI to address a significant portion of respiratory infections (55-70%) and compete with established therapies like Paxlovid will dictate the program’s commercial viability and overall market impact.

Decoy Therapeutics to Detail 2026 Outlook in Virtual Closing Bell Event

Event summary

  • Decoy Therapeutics CEO Rick Pierce will host a virtual investor event on April 9, 2026, at 4:00 PM ET.
  • The event will feature a corporate overview and business outlook for 2026, with a moderated discussion and live Q&A.
  • A replay of the webcast will be available on the company's website for 90 days.
  • Decoy Therapeutics is developing Designable Multi-Antivirals (D-MAVs™) using the IMP³ACT platform.

The big picture

Decoy Therapeutics' D-MAV approach represents a potential shift in antiviral development, aiming for broad-spectrum efficacy through AI-driven design. The company's reliance on the IMP³ACT platform introduces both opportunity and risk, as its performance will dictate the speed and efficiency of drug development. The virtual event provides a window into the company's progress toward commercialization and its ability to address the ongoing threat of viral outbreaks.

What we're watching

Financial Health
The company's ability to secure sufficient financing remains a key risk, as highlighted in the forward-looking statements, and will be a focal point during the event.
Regulatory Risk
The success of Decoy's development plans hinges on navigating potential issues with IND application processes, which could significantly impact timelines and costs.
Platform Scalability
The effectiveness and scalability of the IMP³ACT platform will be critical to Decoy's ability to rapidly develop and deploy new antiviral candidates.

Decoy Therapeutics Avoids Delisting, Faces Nasdaq Monitoring

Event summary

  • Decoy Therapeutics regained compliance with Nasdaq’s minimum bid price requirement on March 31, 2026.
  • The company received notification of compliance from Nasdaq Stock Market LLC.
  • Decoy will now be subject to a Mandatory Panel Monitor for one year.
  • If the minimum bid price requirement is not maintained during the monitoring period, Decoy faces potential delisting.

The big picture

Decoy’s experience highlights the precarious position of smaller biotech firms navigating Nasdaq listing requirements. The imposition of a Mandatory Panel Monitor signals ongoing regulatory oversight and underscores the vulnerability of companies with volatile share prices. This situation could deter institutional investors and limit access to capital markets.

What we're watching

Financial Performance
The company's ability to sustain a share price above the minimum threshold will hinge on demonstrating tangible progress in its drug development programs and securing additional funding.
Governance Scrutiny
The Mandatory Panel Monitor will likely intensify scrutiny of Decoy’s financial controls and reporting practices, potentially impacting management bandwidth and operational flexibility.
Investor Sentiment
Investor confidence, already likely fragile given the prior non-compliance, will be heavily influenced by the company’s progress during the monitoring period and the perceived risk of future delisting.

Decoy Therapeutics Accelerates Antiviral Design with Google Cloud-Powered AI Platform

Event summary

  • Decoy Therapeutics has partnered with Quantori to build a Google Cloud-native platform for peptide design and molecular simulation.
  • Google Cloud is providing funding for the project.
  • The platform is expected to increase Decoy's computational peptide design bandwidth by 25-100x.
  • The new platform integrates Decoy's IMP³ACT engine with advanced protein folding models and molecular dynamics simulations.

The big picture

Decoy's partnership reflects a broader trend in drug discovery, where computational power and AI are increasingly critical for accelerating research and development. The reliance on Google Cloud funding highlights the growing importance of cloud infrastructure in biotech innovation, and the 25-100x bandwidth increase could significantly impact Decoy's ability to compete in the crowded antiviral market, particularly given the ongoing need for broad-spectrum solutions.

What we're watching

Execution Risk
The actual speedup in peptide design will depend on the seamless integration of Quantori’s Q-Suite and Decoy’s IMP³ACT engine, and the platform’s ability to handle the complexity of D-MAV design.
Competitive Landscape
The rapid evolution of AI-driven molecular design tools will require Decoy to continually adapt and upgrade the platform to maintain its competitive edge, potentially increasing operational costs.
Data Dependency
Decoy’s ability to effectively incorporate its proprietary structure-function data into the design process will be crucial for realizing the platform’s full potential and driving the development of novel antiviral candidates.

Decoy Therapeutics Executes Reverse Split to Maintain Nasdaq Listing

Event summary

  • Decoy Therapeutics (DCOY) will implement a 1-for-12 reverse stock split effective March 6, 2026.
  • The split aims to regain compliance with the Nasdaq’s $1.00 minimum bid price requirement.
  • Shareholders approved the reverse split range (1-for-4 to 1-for-15) at a meeting on February 24, 2026.
  • The split will reduce outstanding shares from approximately 6.38 million to roughly 532,000.
  • Options, warrants, and equity plans will be adjusted proportionally to the reverse split.

The big picture

Decoy Therapeutics' reverse stock split is a common, albeit often unwelcome, maneuver for companies facing Nasdaq delisting risks. It underscores the challenges faced by early-stage biopharma firms in maintaining market capitalization, particularly those reliant on non-dilutive funding sources like grants and awards. While the split temporarily addresses the listing requirement, it doesn't resolve the underlying issues of funding and clinical progress that led to the price decline.

What we're watching

Listing Stability
The success of the reverse split hinges on whether it sustainably elevates the share price above the $1.00 threshold, avoiding further delisting concerns.
Investor Sentiment
How institutional and retail investors react to the split will be crucial, as reverse splits often signal underlying financial distress and can trigger selling pressure.
Pipeline Progress
Ultimately, Decoy's stock performance will depend on demonstrating tangible progress in its preclinical pipeline and attracting further investment to support development.

Decoy Therapeutics Broadens Investor Outreach via Webull Platform

Event summary

  • Decoy Therapeutics (DCOY) has joined Webull's Corporate Connect Service (CCS) platform.
  • The platform will be used to distribute corporate communications, including news, earnings reports, and presentations.
  • Webull serves over 24 million registered users across 14 markets.
  • Decoy’s pipeline focuses on respiratory viruses and GI cancers, utilizing ML/AI and peptide conjugate therapeutics.

The big picture

Decoy Therapeutics' adoption of Webull CCS reflects a growing trend of biotech companies seeking to engage directly with retail investors, bypassing traditional IR channels. This move is particularly notable given Webull’s significant global user base and its focus on accessibility. While offering potential benefits in terms of investor outreach, it also introduces new challenges related to managing a broader, potentially less sophisticated shareholder base.

What we're watching

Adoption Rate
The effectiveness of this new channel will depend on Decoy's ability to drive engagement and adoption among its existing and potential investors on Webull.
Transparency Impact
Increased transparency through Webull may influence investor sentiment and valuation, particularly given Decoy's preclinical stage and reliance on non-dilutive funding.
Competitive Landscape
The move signals a broader trend of biotech companies leveraging retail-focused platforms; whether this becomes a standard practice will impact investor access and information asymmetry.

Decoy Therapeutics to Spotlight Antiviral Pipeline at Webull Webinar

Event summary

  • Decoy Therapeutics will present at the Webull Financial Corporate Connect Webinar Series on February 10, 2026.
  • CEO Rick Pierce will focus on the company’s antiviral therapeutics targeting multiple pathogens with a single drug.
  • The presentation is scheduled for 1:20 PM EST.
  • Webull Financial serves tens of millions of users across over 180 countries.

The big picture

Decoy Therapeutics’ participation in a Webull-hosted webinar signals a strategic effort to increase visibility among retail investors, a departure from the company’s previous reliance on institutional funding. The company’s focus on AI-driven drug design and broad-spectrum antiviral therapeutics aligns with the broader trend of leveraging technology to accelerate drug development, but the preclinical stage of its pipeline introduces significant execution risk. The partnership with Webull, a brokerage with a substantial user base, suggests a desire to tap into a wider pool of capital.

What we're watching

Pipeline Validation
The webinar provides an opportunity for Decoy to publicly articulate the potential of its platform, but the lack of clinical data raises questions about the viability of its approach.
Investor Relations
Webull’s reach suggests Decoy is attempting to broaden its investor base, but the company’s reliance on non-dilutive funding warrants scrutiny.
Competitive Landscape
The focus on broad-spectrum antivirals will likely draw comparisons to other companies pursuing similar strategies, and Decoy’s ability to differentiate its technology will be key.

Decoy Therapeutics Secures Gates Foundation Funding for Global Manufacturing Platform

Event summary

  • Decoy Therapeutics participated in a virtual investor segment to detail its Global Access Commitment Agreement (GACA) with the Gates Foundation.
  • The agreement funds the development of a flexible, scalable manufacturing platform for peptide-conjugate antivirals.
  • The platform leverages Decoy's IMP3ACT™ technology and aims to expand access to therapeutics in low- and middle-income countries.
  • The platform's 'design-for-manufacturing' approach will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor.
  • Decoy Therapeutics is a preclinical-stage company focused on respiratory viruses and GI cancers, backed by institutional investors and non-dilutive funding.

The big picture

Decoy's partnership with the Gates Foundation highlights the growing trend of philanthropic organizations investing in biopharmaceutical manufacturing capacity to address global health crises. This initiative signals a shift towards decentralized, agile production models, moving away from traditional, centralized pharmaceutical manufacturing. The agreement provides Decoy with crucial non-dilutive funding and validation for its IMP3ACT™ platform, but also carries the responsibility of delivering accessible therapeutics to underserved populations, which could present unique operational and ethical challenges.

What we're watching

Manufacturing Scale
The success of Decoy's GACA hinges on the ability to rapidly scale the new manufacturing platform, a complex process with potential bottlenecks and cost overruns that could impact timelines.
Regulatory Approval
The validation of the platform using the pan-coronavirus inhibitor will be critical, and any delays or setbacks in clinical trials or regulatory approvals could significantly impact the program's viability.
Geopolitical Risk
The focus on low- and middle-income countries introduces geopolitical and logistical risks that could affect distribution and adoption of therapeutics, potentially impacting Decoy's long-term financial returns.

Decoy Therapeutics Secures Gates Foundation Funding for Global Manufacturing Platform

Event summary

  • Decoy Therapeutics has entered a Global Access Commitment Agreement (GACA) with the Gates Foundation.
  • The agreement funds the development of a globally accessible, scalable manufacturing platform for peptide-conjugate antivirals.
  • The platform will enable rapid response to viral outbreaks and support Decoy's commercial efforts in global markets.
  • Decoy is collaborating with contract manufacturing organizations in the U.S. and Europe to establish the platform.
  • The platform will be validated using Decoy’s intranasal pan-coronavirus fusion inhibitor.

The big picture

Decoy’s partnership with the Gates Foundation signals a growing trend of biopharmaceutical companies prioritizing global health access alongside commercial interests. The development of a flexible, scalable manufacturing platform addresses a critical bottleneck in pandemic preparedness, potentially reducing reliance on concentrated production hubs. This initiative also highlights the increasing importance of ‘design-for-manufacturing’ approaches in drug development, aiming to accelerate timelines and reduce costs.

What we're watching

Manufacturing Scale
The success of this initiative hinges on Decoy’s ability to rapidly and cost-effectively scale up manufacturing capabilities through its contract manufacturing partners, a process often fraught with challenges.
Regulatory Approval
The FDA’s review of Decoy’s pan-coronavirus antiviral IND application will be a critical indicator of the platform’s viability and the company’s regulatory strategy.
Geopolitical Risk
The distributed manufacturing network’s effectiveness will be tested by potential geopolitical instability and supply chain disruptions, which could impact the platform's responsiveness.
CID: 663